Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing
2023; BioMed Central; Volume: 12; Issue: 1 Linguagem: Inglês
10.1186/s40164-023-00402-5
ISSN2162-3619
AutoresWei Li, Binglei Zhang, Weijie Cao, Wenli Zhang, Tiandong Li, Lina Liu, Linping Xu, Fengcai Gao, Yanmei Wang, Fang Wang, Haizhou Xing, Zhongxing Jiang, Jianxiang Shi, Zhilei Bian, Yongping Song,
Tópico(s)Multiple Myeloma Research and Treatments
ResumoBCMA CAR-T is highly effective for relapsed/refractory multiple myeloma(R/R-MM) and significantly improves the survival of patients. However, the short remission time and high relapse rate of MM patients treated with BCMA CAR-T remain bottlenecks that limit long-term survival. The immune microenvironment of the bone marrow (BM) in R/R-MM may be responsible for this. The present study aims to present an in-depth analysis of resistant mechanisms and to explore potential novel therapeutic targets for relapse of BCMA CAR-T treatment via single-cell RNA sequencing (scRNA-seq) of BM plasma cells and immune cells.
Referência(s)